Mesoblast Ltd (ASX:MSB) Share Price

Company Profile

Business description
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
Contact
55 Collins Street
Level 38
MelbourneVIC3000
AUS
T: +61 396396036
E: michael.schuster@mesoblast.com
https://www.mesoblast.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
73

Recommended

Morningstar analysts see value in several stocks under fire from shorts.

Lewis Jackson | 12 January 2022

Morningstar had forecast big losses for the drugmaker, which has been dropped from the ASX 200.

Emma Rapaport | 15 June 2020

The biotech giant has jumped 22pc a year for the past decade but new players are emerging.

Nicki Bourlioufas | 07 April 2019

Index	Last price	Change	% Change
All Ordinaries	7,847.60	205.10	-2.55%
CAC 40	7,241.48	357.50	-4.70%
DAX 40	20,567.86	1,149.53	-5.29%
Dow JONES (US)	38,591.16	1,954.77	-4.82%
FTSE 100	8,045.37	429.37	-5.07%
HKSE	22,849.81	352.72	-1.52%
NASDAQ	15,676.78	873.82	-5.28%
Nikkei 225	33,780.58	955.35	-2.75%
NZX 50 Index	12,225.28	113.29	-0.92%
S&P 500	5,107.30	289.22	-5.36%
S&P/ASX 200	7,667.80	191.90	-2.44%
SSE Composite Index	3,342.01	8.12	-0.24%